| New 1, 2, 3, 4-tetrahydropyrrolo [3, 4-b] indole derivatives as selective CB2 receptor agonists D Pagé, H Yang, W Brown, C Walpole, M Fleurent, M Fyfe, F Gaudreault, ... Bioorganic & medicinal chemistry letters 17 (22), 6183-6187, 2007 | 73 | 2007 |
| Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus VP Werth, RA Furie, J Romero-Diaz, S Navarra, K Kalunian, ... New England Journal of Medicine 387 (4), 321-331, 2022 | 60 | 2022 |
| Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242 M Ranganathan, N DeMartinis, B Huguenel, F Gaudreault, MM Bednar, ... Molecular psychiatry 22 (11), 1633-1640, 2017 | 43 | 2017 |
| Systems approach reveals photosensitivity and PER 2 level as determinants of clock‐modulator efficacy DW Kim, C Chang, X Chen, AC Doran, F Gaudreault, T Wager, ... Molecular Systems Biology 15 (7), e8838, 2019 | 35 | 2019 |
| A population pharmacokinetic model for the complex systemic absorption of ropivacaine after femoral nerve block in patients undergoing knee surgery F Gaudreault, P Drolet, M Fallaha, F Varin Journal of pharmacokinetics and pharmacodynamics 39, 635-642, 2012 | 24 | 2012 |
| The reliability of the current perception threshold in volunteers and its applicability in a clinical setting F Gaudreault, P Drolet, M Fallaha, F Varin Anesthesia & Analgesia 120 (3), 678-683, 2015 | 22 | 2015 |
| OP0193 BIIB059, a humanized monoclonal antibody targeting BDCA2 on plasmacytoid dendritic cells (pDC), shows dose-related efficacy in the phase 2 LILAC study in patients (pts … V Werth, R Furie, J Romero-Diaz, S Navarra, K Kalunian, ... Annals of the Rheumatic Diseases 79 (Suppl 1), 120-121, 2020 | 19 | 2020 |
| High-performance liquid chromatography using UV detection for the simultaneous quantification of ropivacaine and bupivacaine in human plasma F Gaudreault, P Drolet, F Varin Therapeutic drug monitoring 31 (6), 753-757, 2009 | 17 | 2009 |
| Modeling the anesthetic effect of ropivacaine after a femoral nerve block in orthopedic patients: a population pharmacokinetic–pharmacodynamic analysis F Gaudreault, P Drolet, M Fallaha, F Varin Anesthesiology 122 (5), 1010-1020, 2015 | 10 | 2015 |
| BIIB059, a humanized monoclonal antibody targeting blood dendritic cell antigen 2 on plasmacytoid dendritic cells, shows dose-related efficacy in a phase 2 study in … V Werth, R Furie, J Romero-Diaz, S Navarra, K Kalunian, ... ARTHRITIS & RHEUMATOLOGY 72, 2020 | 9 | 2020 |
| The safety and efficacy of PF-04958242 in age-related sensorineural hearing loss: a randomized clinical trial MM Bednar, N DeMartinis, A Banerjee, S Bowditch, F Gaudreault, ... JAMA Otolaryngology–Head & Neck Surgery 141 (7), 607-613, 2015 | 9 | 2015 |
| Investigation of CYP3A induction by PF‐05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response J Lin, F Gaudreault, N Johnson, Z Lin, P Nouri, TC Goosen, ... Clinical and Translational Science 15 (9), 2184-2194, 2022 | 1 | 2022 |
| Quantitative understanding of the longitudinal relationship between short-term MRI outcomes and long-term clinical outcomes measures in multiple sclerosis M Wiens, AH Maghzi, N Mangal, KK Muralidharan, H Naik, J French, ... MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 738-739, 2021 | 1 | 2021 |
| Prospective application and validation of a systems pharmacology model to guide the clinical development of PF-05251749: a casein kinase 1 (CK1) inhibitor F Gaudreault, A Simen, E Pickering, D Volfson, T Wager, J Kim, KA Kim, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S14-S15, 2018 | 1 | 2018 |
| Pharmacométrie de la ropivacaïne suivant l'anesthésie locorégionale chez les patients orthopédiques: Caractérisation de l'intensité et de la durée du bloc sensitif F Gaudreault Universite de Montreal (Canada), 2014 | 1 | 2014 |
| Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus F Gaudreault, H Naik US Patent App. 18/038,911, 2024 | | 2024 |
| MODEL-INFORMED DEVELOPMENT OF BIIB104 IN SCHIZOPHRENIA: A POPPK APPROACH TO SUPPORT ENROLMENT OF JAPANESE SUBJECTS IN PHASE 2 F Gaudreault, M Rooney, E Fossale, E Arce, C Shaffer CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S11-S12, 2021 | | 2021 |
| FRI0204 SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC EFFECT OF BIIB059, A MONOCLONAL ANTIBODY TARGETING BDCA2 FOLLOWING ADMINISTRATION OF SUBCUTANEOUS SINGLE DOSES … C Musselli, F Gaudreault, H Naik, H Carroll, A Sharma, X Huang, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 781-781, 2019 | | 2019 |
| Hitting the Moving Target in Circadian Rhythm: The Application of Systems Pharmacology Model in the Development of a CK1 Inhibitor C Chang, F Gaudreault, A Simen, T Wager, J Kim, KA Kim, T Park, ... JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S76-S76, 2017 | | 2017 |
| Safety, Pharmacokinetics (PK) and Clinical Effects of PF-04958242, an alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Positive Allosteric Modulator (PAM) in … B Evans, N DeMartinis, F Gaudreault, J Mancuso, L Zumpano, D Walling, ... NEUROPSYCHOPHARMACOLOGY 41, S415-S415, 2016 | | 2016 |
Travis T WagerRgenta Therapeutics/Pfizer Inc.Verified email at rgentatx.com
